Risankizumab for Ulcerative Colitis—Reply

Authors

Institutions

Publication Details

Journal
JAMA
Published
2025-01-22
DOI
https://doi.org/10.1001/jama.2024.25643
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risankizumab for Ulcerative Colitis—Reply

Jasmina Kalabic, Edward V. Loftus, Édouard Louis
JAMA
Inflammatory Bowel Disease
article

Risankizumab for Ulcerative Colitis—Reply

Jasmina Kalabic, Edward V. Loftus, Édouard Louis
article en

Abstract

No abstract available for this paper.
JAMAVol. 333(7)
Mayo Clinic (US), AbbVie (Germany) (DE), Centre Hospitalier Universitaire de Liège (BE)
Openalex Percentile: Top 98%
Inflammatory Bowel Disease
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Risankizumab for Ulcerative Colitis—Reply — Jasmina Kalabic, Edward V. Loftus, et al. · JAMA (2025) | TGRS Research Map | TGRS